ACXP Stock Summary and Trading Ideas (Acurx Pharmaceuticals | NASDAQ:ACXP)

Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.

Acurx Pharmaceuticals trades on the NASDAQ stock market under the symbol ACXP.

As of January 16, 2026, ACXP stock price declined to $2.65 with 15,399 million shares trading.

ACXP has a beta of 0.96, meaning it tends to be less sensitive to market movements. ACXP has a correlation of 0.02 to the broad based SPY ETF.

ACXP has a market cap of $5.53 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, ACXP traded as high as $176.40 and as low as $2.44.

The top ETF exchange traded funds that ACXP belongs to (by Net Assets): VXF.

ACXP has underperformed the market in the last year with a price return of -83.2% while the SPY ETF gained +18.1%. ACXP has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -62.3% and -4.0%, respectively, while the SPY returned +5.0% and +1.2%, respectively.

ACXP support price is $2.51 and resistance is $2.87 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACXP shares will trade within this expected range on the day.